Immunocore (IMCR)
(Delayed Data from NSDQ)
$33.87 USD
+0.47 (1.41%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $33.81 -0.06 (-0.18%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Balance Sheet
Fiscal Year End for Immunocore Holdings PLC Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 443 | 411 | 327 | 167 | 95 |
Receivables | 52 | 72 | 34 | 30 | 64 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 5 | 1 | 0 | 0 | 0 |
Other Current Assets | 30 | 0 | 0 | 0 | 0 |
Total Current Assets | 529 | 485 | 361 | 196 | 159 |
Net Property & Equipment | 9 | 8 | 12 | 18 | 70 |
Investments & Advances | 0 | 0 | 0 | 1 | 1 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 11 | 5 | 4 | 3 | 2 |
Intangibles | 0 | 1 | 0 | 0 | 0 |
Deposits & Other Assets | 14 | 9 | 7 | 6 | 6 |
Total Assets | 597 | 539 | 415 | 253 | 237 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 18 | 93 | 49 | 33 | 38 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 24 |
Current Portion Capital Leases | 0 | 2 | 2 | 3 | 2 |
Accrued Expenses | 120 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 35 | 37 |
Other Current Liabilities | 0 | 8 | 34 | 0 | 7 |
Total Current Liabilities | 139 | 103 | 84 | 71 | 108 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 6 | 5 | 9 | 32 | 61 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 48 | 49 | 51 | 47 | 0 |
Non-Current Capital Leases | 0 | 35 | 35 | 32 | 49 |
Other Non-Current Liabilities | 1 | 2 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 228 | 194 | 179 | 182 | 218 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,150 | 153 | 292 | 496 | 362 |
Retained Earnings | -745 | -323 | -662 | -449 | -356 |
Other Equity | -36 | 515 | 606 | 24 | 14 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 369 | 345 | 236 | 71 | 19 |
Total Liabilities & Shareholder's Equity | 597 | 539 | 415 | 253 | 237 |
Total Common Equity | 369 | 345 | 236 | 71 | 19 |
Shares Outstanding | 49.70 | 48.00 | 43.80 | NA | NA |
Book Value Per Share | 7.42 | 7.18 | 5.39 | 0.00 | 0.00 |
Fiscal Year End for Immunocore Holdings PLC Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 860 | 833 | 443 | 461 | 429 |
Receivables | 60 | 58 | 52 | 63 | 64 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 4 | 5 | 2 | 2 |
Other Current Assets | 34 | 31 | 30 | 0 | 0 |
Total Current Assets | 957 | 926 | 529 | 526 | 495 |
Net Property & Equipment | 8 | 8 | 9 | 10 | 10 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 10 | 11 | 11 | 5 | 6 |
Intangibles | 0 | 0 | 0 | 2 | 1 |
Deposits & Other Assets | 16 | 16 | 14 | 11 | 10 |
Total Assets | 1,023 | 994 | 597 | 588 | 551 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 20 | 16 | 18 | 118 | 107 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 1 | 1 |
Current Portion Capital Leases | 0 | 1 | 0 | 2 | 2 |
Accrued Expenses | 164 | 139 | 120 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 1 |
Other Current Liabilities | 0 | 0 | 0 | 2 | 4 |
Total Current Liabilities | 185 | 155 | 139 | 124 | 116 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 5 | 5 | 6 | 5 | 5 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 438 | 438 | 48 | 49 | 46 |
Non-Current Capital Leases | 33 | 0 | 0 | 37 | 35 |
Other Non-Current Liabilities | 2 | 1 | 3 | 2 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 664 | 634 | 228 | 218 | 204 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,174 | 1,164 | 1,150 | 185 | 173 |
Retained Earnings | -781 | -769 | -745 | -367 | -366 |
Other Equity | -34 | -35 | -36 | 551 | 540 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 359 | 360 | 369 | 369 | 347 |
Total Liabilities & Shareholder's Equity | 1,023 | 994 | 597 | 588 | 551 |
Total Common Equity | 359 | 360 | 369 | 369 | 347 |
Shares Outstanding | 50.00 | 50.00 | 49.70 | 48.90 | 48.90 |
Book Value Per Share | 7.18 | 7.19 | 7.42 | 7.55 | 7.10 |